Handok, AEterna Zentaris sign licensing agreement over oral anti-cancer agent
Published: 2009-04-29 06:57:00
Updated: 2009-04-29 06:57:00
Handok Pharm announced on April 23 announced the signing of a licensing agreement with Canada based AEterna Zentaris Inc. to distribute Perifosine in Korea, a novel, potentially first-in-class, oral anti-cancer agent that was developed by AEterna Zentaris.
Æterna Zentaris is a global biopharma...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
